Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. (Q33379225)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Richard A. Larson

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

16

object named as

T Hughes

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

M Baccarani

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M Deininger

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J F Apperley

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J H Lipton

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

S L Goldberg

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

S Corm

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

N P Shah

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

F Cervantes

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R T Silver

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D Niederwieser

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R M Stone

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

H Dombret

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

L Roy

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M C Müller

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R Ezzeddine

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A M Countouriotis

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

H M Kantarjian

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

10 April 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1200-1206

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

https://scigraph.springernature.com/pub.10.1038/leu.2008.84

0 references

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to imatinib: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2008.84

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18401416%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33379225&oldid=1694329228"